Precision NanoSystems - Formulation Development Europe Solutions/Service Company
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Precision NanoSystems: Maximizing the Value of Lipid Nanoparticle Genomics

Lloyd Jeffs Ph.D, Senior Director of Biopharmaceutical Services, Precision NanoSystemsLloyd Jeffs Ph.D, Senior Director of Biopharmaceutical Services
The world of genomic medicine is witnessing a revolution in the invention, discovery and enhancement of new treatment modalities that is driving tremendous growth in the field. Long-term drivers of this transformation include novel approaches to cell and gene therapies, but most recently, the COVID-19 pandemic has accelerated the commercialization of mRNA-LNP (lipid nanoparticles) technology formulations as safe and effective vaccines. One of the forerunners actualizing nanomedicine innovation, research, and development is Precision NanoSystems who is offering end-to-end solutions to lipid nanoparticle genomics medicine developers. Vancouver-based Precision NanoSystems is a global leader in technologies, solutions and contract services for developing Lipid Nanoparticles for genomic medicines, including mRNA vaccines and therapeutics. The company has a long history of technology and product innovation and has made genomic medicines and nanoparticle drug delivery accessible to mainstream drug developers across the globe. The company also provides a plethora of value-added services, including proprietary RNA lipid delivery formulations, contract formulation services and microfluidic instruments for particle formation.

Precision NanoSystems’ proven technologies increase the consistency, reproducibility and quality of lipid nanoparticle-delivered genomic medicines lowering the barrier to entry and accelerating timelines to take genomic drugs from concept to clinic. In addition, the company’s technical support, manufacturing systems and biopharmaceutical services enable pharmaceutical companies to move from lead formulations to clinical validation faster and more efficiently. Many emerging drug companies struggle to book time with CDMOs and have aggressive timelines to generate data. Precision NanoSystems biopharmaceutical contract services enable these drug companies to develop and optimize their formulations from an early stage and contract manufacture phase one and phase two of the drug product for clinic.

Leveraging scalable technologies, the world’s leading drug developers are building a robust and practical roadmap for genomic medicines with accelerated mRNA-LNP process development and manufacturing. Precision NanoSystems’ flagship NanoAssemblr® platform is a suite of four instruments, NanoAssemblr® SparkTM, IgniteTM, BlazeTM, and GMP System provide seamless microfluidic mixing for rapid screening and drug discovery to large-scale clinical manufacturing of nanomedicine drug products. The proprietary NxGenTM microfluidic mixers at the heart of NanoAssemblr® platforms are designed specifically for genomic medicine development. Using NxGenTM microfluidic technology, researchers can control and precisely assemble high-quality, uniform lipid nanoparticles (LNPs), ensuring reproducible scale-up of mRNA lipid nanoparticles and other complex formulations for preclinical studies.

Precision NanoSystems’ lipid nanoparticle (LNP) portfolio also offers researchers and drug developers turnkey access to GenvoyTM lipid nanoparticle delivery reagents and custom formulations.
The GenvoyTM platform includes a proprietary lipid formulation library that enables, de-risks, and accelerates drug development programs. The lipid library consists of an array of ionizable cationic lipids that allow formulations to be tailored specifically to the intended therapeutic application.

Collectively these technologies comprise the company’s Genomic Medicine Toolkit that uniquely enables access to ionizable lipids, LNP manufacturing technology, and expertise to develop any desired lipid nanoparticle drug.

Precision NanoSystems takes pride in being able to support and educate its clients to deliver optimized lipid nanoparticle formulations, maximizing productivity and advancing the quality of modern patient care. Precision NanoSystems biopharmaceutical contract services provide complete analytical and regulatory support for a robust, scalable, end-to-end genomic medicine manufacturing process. Backed by an expert team of scientists, process engineers and scalable technologies, the biopharmaceutical contract services team supports the development of custom analytical methods for nanoparticle formulations and assists with generating data for POC, preclinical, or clinical milestones for accelerated clinical trials. Additionally, the company’s clients can leverage comprehensive knowledge and insights with on-site training and support for their clinical application scientists. Precision NanoSystems is a one-stop-shop solution for all genomic medicine developments. The company offers a total package for its clients, who can avoid delays and maintain control over process know-how by working with one vendor with excellent tech transfer capabilities.

Precision NanoSystems is proud to contribute to the rapid global growth of transformative genomic medicines by providing a proven suite of products, tools and services, including the NanoAssemblr® platform, GenVoy Delivery portfolio and Biopharmaceutical contract services

The company greatly benefits from Dr. Lloyd Jeffs’s extensive experience, who joined Precision NanoSystems in June 2018. His Biopharma Contract Services team is responsible for developing and executing custom programs to meet the clinical manufacturing needs of clients. Dr. Jeffs is an expert in developing lipid-based nanotherapeutics and has over 20 years of experience in this field, including formulation and process development, scale-up and technology transfer. “If there is a nucleic acid, whether DNA or RNA, we’ve probably formulated it,” humors Dr. Lloyd Jeffs. He shares the same passion as the rest of the Precision NanoSystems leadership team, helping clients translate technology into innovative clinical products. He further proudly states that Precision NanoSystems has completed 160+ contract services projects and contributed to the nanomedicine industry’s growth with solutions, including the NanoAssemblr® platform, a suite of nanomedicine development technology that provides seamless microfluidic mixing and manufacturing of nanoparticles. Over 800 NanoAssemblr® instruments have been installed in companies and academic institutions worldwide, including government labs.

Precision NanoSystems, is now part of Danaher Life Sciences Group, which offers complementary portfolios from equipment and consumables to fully flexible manufacturing solutions that support all stages in the genomic medicine manufacturing workflow. The company promises to continually strive towards innovating truly comprehensive, end-to-end drug development and manufacturing solutions.
Share this Article:
Top 10 Formulation Development Outsourcing Companies in Europe - 2022

Company
Precision NanoSystems

Headquarters
Vancouver, British Columbia

Management
Lloyd Jeffs Ph.D, Senior Director of Biopharmaceutical Services

Description
Precision NanoSystems is a global leader in technologies, solutions, and services for the development of lipid nanoparticle-based genomic medicines, including mRNA vaccines and therapeutics. It supports biopharma companies who are ushering in the next wave of genomic medicines for infectious diseases, cancer, and rare diseases.

Precision NanoSystems